SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt. / Feldt-Rasmussen, Bo; Borg, Rikke; Carstens, Jan; Hansen, Ditte; Hornum, Mads; Lindhardt, Morten; Mose, Frank Holden; Pedersen, Birgitte Bang; Poulsen, Johan Vestergaard; Schandorff, Kristine Dyhr; Strandhave, Charlotte.

I: Ugeskrift for Laeger, Bind 184, Nr. 16, V11210887, 18.04.2022.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Feldt-Rasmussen, B, Borg, R, Carstens, J, Hansen, D, Hornum, M, Lindhardt, M, Mose, FH, Pedersen, BB, Poulsen, JV, Schandorff, KD & Strandhave, C 2022, 'SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt', Ugeskrift for Laeger, bind 184, nr. 16, V11210887. <https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2022-04/v11210887_web.pdf>

APA

Feldt-Rasmussen, B., Borg, R., Carstens, J., Hansen, D., Hornum, M., Lindhardt, M., Mose, F. H., Pedersen, B. B., Poulsen, J. V., Schandorff, K. D., & Strandhave, C. (2022). SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt. Ugeskrift for Laeger, 184(16), [V11210887]. https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2022-04/v11210887_web.pdf

Vancouver

Feldt-Rasmussen B, Borg R, Carstens J, Hansen D, Hornum M, Lindhardt M o.a. SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt. Ugeskrift for Laeger. 2022 apr. 18;184(16). V11210887.

Author

Feldt-Rasmussen, Bo ; Borg, Rikke ; Carstens, Jan ; Hansen, Ditte ; Hornum, Mads ; Lindhardt, Morten ; Mose, Frank Holden ; Pedersen, Birgitte Bang ; Poulsen, Johan Vestergaard ; Schandorff, Kristine Dyhr ; Strandhave, Charlotte. / SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt. I: Ugeskrift for Laeger. 2022 ; Bind 184, Nr. 16.

Bibtex

@article{b6132084a27349649739d74577d21168,
title = "SGLT2-h{\ae}mning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt",
abstract = "This review summarises the current knowledge of electroconvulsive therapy (ECT) which is still the most potent and fast-acting antidepressant intervention. The modern procedure is safe when general precautions are taken. Cognitive side effects are transient in most patients, and concerns about side effects should not prevent relevant use. Due to the prognostic benefits of rapid remission, ECT should, in relevant patients, be considered early in the treatment course. Patients should be offered maintenance pharmacotherapy, and, in high-risk cases, tapering of the acute ECT course or maintenance ECT, in order to reduce the risk of relapse.",
keywords = "Diabetes Mellitus, Electroconvulsive Therapy/adverse effects, Female, Heart Failure/drug therapy, Humans, Male, Renal Insufficiency, Chronic/complications, Sodium-Glucose Transporter 2",
author = "Bo Feldt-Rasmussen and Rikke Borg and Jan Carstens and Ditte Hansen and Mads Hornum and Morten Lindhardt and Mose, {Frank Holden} and Pedersen, {Birgitte Bang} and Poulsen, {Johan Vestergaard} and Schandorff, {Kristine Dyhr} and Charlotte Strandhave",
year = "2022",
month = apr,
day = "18",
language = "Dansk",
volume = "184",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "16",

}

RIS

TY - JOUR

T1 - SGLT2-hæmning til kronisk nyresygdom uden ledsagende diabetes eller hjertesvigt

AU - Feldt-Rasmussen, Bo

AU - Borg, Rikke

AU - Carstens, Jan

AU - Hansen, Ditte

AU - Hornum, Mads

AU - Lindhardt, Morten

AU - Mose, Frank Holden

AU - Pedersen, Birgitte Bang

AU - Poulsen, Johan Vestergaard

AU - Schandorff, Kristine Dyhr

AU - Strandhave, Charlotte

PY - 2022/4/18

Y1 - 2022/4/18

N2 - This review summarises the current knowledge of electroconvulsive therapy (ECT) which is still the most potent and fast-acting antidepressant intervention. The modern procedure is safe when general precautions are taken. Cognitive side effects are transient in most patients, and concerns about side effects should not prevent relevant use. Due to the prognostic benefits of rapid remission, ECT should, in relevant patients, be considered early in the treatment course. Patients should be offered maintenance pharmacotherapy, and, in high-risk cases, tapering of the acute ECT course or maintenance ECT, in order to reduce the risk of relapse.

AB - This review summarises the current knowledge of electroconvulsive therapy (ECT) which is still the most potent and fast-acting antidepressant intervention. The modern procedure is safe when general precautions are taken. Cognitive side effects are transient in most patients, and concerns about side effects should not prevent relevant use. Due to the prognostic benefits of rapid remission, ECT should, in relevant patients, be considered early in the treatment course. Patients should be offered maintenance pharmacotherapy, and, in high-risk cases, tapering of the acute ECT course or maintenance ECT, in order to reduce the risk of relapse.

KW - Diabetes Mellitus

KW - Electroconvulsive Therapy/adverse effects

KW - Female

KW - Heart Failure/drug therapy

KW - Humans

KW - Male

KW - Renal Insufficiency, Chronic/complications

KW - Sodium-Glucose Transporter 2

M3 - Review

C2 - 35485777

VL - 184

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 16

M1 - V11210887

ER -

ID: 327138264